Summary
T. Rowe Price Biotech ETF is an ETF - a fund traded on an exchange like a stock - run by T. Rowe. Positions inside: 87. The ten largest make up 29% of the fund.
- Yearly costs
- 0.55%
- Fund size
- $9.66M
- Positions
- 87
- Running since
- 2026
What speaks for it
Nothing stands out in its favour.
What to watch
- 89% of the fund is in one country (United States).
- Costs of 0.55% a year are above the middle of comparable funds (0.44%).
- A young fund: it has been running only since 2026.
- A small fund with $9.66M under management; small funds get closed more often.
- It trades little: only about $47.8K changes hands a day.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -6.2%
- Avg. market cap
- $25.4B
- P/E
- -
- Forward P/E
- -
- P/S
- 13.8x
- P/B
- 6.1x
- P/FCF
- -
- EV/EBITDA
- -
- Dividend yield
- 0.03%
- ROIC
- -24.3%
- ROE
- -41.6%
- Gross margin
- -889.9%
- Operating margin
- -6,031.8%
- Net margin
- -5,138.0%
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.00
Weighted average of the 50 largest companies, which make up 81% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Widely spread- 1 ARArgenx ARGX 5.1%
- 2 KYKymera Therapeutics KYMR 4.2%
- 3 KOKodiak Sciences Inc. KOD 2.7%
- 4 NTNatera NTRA 2.5%
- 5 MRModerna MRNA 2.5%
- 6 INInsmed INSM 2.4%
- 7 VRVertex Pharmaceuticals VRTX 2.3%
- 8 UTUnited Therapeutics UTHR 2.3%
- 9 RVRevolution Medicines RVMD 2.3%
- 10 PCVaxcyte PCVX 2.3%
Positions in the fund: 87. The ten largest make up 29% of it.
Composition as of Oct 18, 2026.
Where is it spread?
One countryBy country
- United States 89%
- Netherlands 5.1%
- Ireland 1.6%
- United Kingdom 1.4%
- Other countries 3.0%
By company size
- Mega cap 1.0%
- Large cap 33%
- Mid cap 54%
- Small cap 11%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest country: United States (89%). Largest size group: Mid cap (54%).
What does it cost me?
Expensive- A year from $10,000
- $55.00
- Over 20 years
- $2,646
From every $10,000 invested the fund takes $55.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $2,646.
How has it done?
- Deepest drop
- -11%
It has traded for less than a year, too short to judge.
Does it pay dividends?
We have no record of payments from this fund.
Is it easy to buy and sell?
It trades little- Traded a day
- $47.8K
- Shares a day
- 2.0K
On an average day about $47.8K of the fund changes hands.
How expensive are the companies inside?
Rather expensive- Average Bulios Score
- 43 out of 100
Weight by Bulios Fair Price
- Undervalued 20%
- Fairly valued 4.6%
- Overvalued 75%
By Fair Price, 75% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 81% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
XB XBI SPDR S&P Biotech ETF | United States | 0.35% | $7.55B | +34% | Pays out | 58% |
CU CURE.AX Global X - S&P Biotech ETF | Australia | 0.45% | $27.4M | +25% | Reinvests | 58% |
LA LABU Direxion Daily S&P Biotech Bull 3X Shares | United States | 0.96% | $1.06B | +73% | Pays out | 46% |
FB FBIOX Fidelity Select Biotechnology Pt· mutual fund | United States | - | $5.81B | +15% | Pays out | 44% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $10.5B | +30% | Pays out | 40% |
FB FBTTX Fidelity Advisor Biotechnology Fund· mutual fund | - | - | $2.29B | +25% | Pays out | 39% |
